Rosuvastatin – The Most Potent and Less Toxic Statin for HIV Patients

Cardiovascular complications have emerged as an important cause of morbidity and mortality in HIV-infected individuals in the Western world, where antiretroviral therapy has halted progression to advance immunodeficiency and development of classic opportunistic illnesses. For this reason, prevention of metabolic abnormalities associated to increased risk of myocardial infarction and stroke have recently attracted much attention in routine HIV care. In this regard, proper management of dyslipidemia and glucose abnormalities is being addressed more intensively in a growing number of patients.